Find Tetrahydrocannabinol manufacturers, exporters & distributors on PharmaCompass

Dronabinol

Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

32 API Suppliers, 22 USDMF, 2 CEP/COS, 10 Listed Suppliers

32 API Suppliers
22 USDMF
2 CEP/COS
10 Listed Suppliers

DEVELOPMENTS

112 Drugs in Development

112 Drugs in Development

INTERMEDIATES

5 Intermediates Suppliers

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

23 FDF Dossiers, 19 FDA Orange Book, 2 Europe, 2 Canada

23 FDF Dossiers
19 FDA Orange Book
2 Europe
2 Canada

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 10MG, CAPSULE;ORAL - 2.5MG, CAPSULE;ORAL - 5MG

drugProductComposition
CAPSULE;ORAL - 10MG
CAPSULE;ORAL - 2.5MG
CAPSULE;ORAL - 5MG

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 Seqens, 8 DKSH, 1 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 5 Actylis, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 9 BASF, 2 Finar, 3 Gangwal Chemicals, 1 Kerry, 3 Lonza Capsugel, 2 Nomisma Healthcare, 1 Pluviaendo, 1 Qualicaps, 2 Roquette, 1 Seppic, 1 Sigachi Industries, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

11 Topical, 10 Thickeners and Stabilizers, 8 Empty Capsules, 8 Coating Systems & Additives, 6 Parenteral, 6 Film Formers & Plasticizers, 6 Controlled & Modified Release, 6 Solubilizers, 5 Fillers, Diluents & Binders, 3 Direct Compression, 3 Coloring Agents, 3 Emulsifying Agents, 2 Lubricants & Glidants, 1 Granulation, 1 Co-Processed Excipients, 1 API Stability Enhancers, 1 Taste Masking

excipientsByApplications
11 Topical
10 Thickeners and Stabilizers
8 Empty Capsules
8 Coating Systems & Additives
6 Parenteral
6 Film Formers & Plasticizers
6 Controlled & Modified Release
6 Solubilizers
5 Fillers, Diluents & Binders
3 Direct Compression
3 Coloring Agents
3 Emulsifying Agents
2 Lubricants & Glidants
1 Granulation
1 Co-Processed Excipients
1 API Stability Enhancers
1 Taste Masking

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 36 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
36 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 7 Finished Drug Prices

globalSalesInformation
3 US Medicaid Prescriptions
7 Finished Drug Prices

MARKET PLACE

8 APIs, 3 FDF Dossiers, 1 EXCIPIENTS

marketPlace
8 APIs
3 FDF Dossiers
1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

4 US Patents

patents
4 US Patents

REF. STANDARDS & IMPURITIES

2 USP , 2 Others

otherSolutions
2 USP
2 Others

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

5INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

112DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

21,240,895

Annual Reports (USD Million)

Finished Drug Prices

50 RELATED EXCIPIENT COMPANIES

81EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Tetrahydrocannabinol, Marinol, Delta9-tetrahydrocannabinol, Delta9-thc, Delta-9-tetrahydrocannabinol, 1972-08-3

Molecular Formula

C₂₁H₃₀O₂

Molecular Weight

314.5 g/mol

InChI Key

CYQFCXCEBYINGO-IAGOWNOFSA-N

FDA UNII

7J8897W37S

A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.

Dronabinol is a Cannabinoid.

1 2D Structure

Tetrahydrocannabinol

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol

2.1.2 InChI

InChI=1S/C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h11-13,16-17,22H,5-10H2,1-4H3/t16-,17-/m1/s1

2.1.3 InChI Key

CYQFCXCEBYINGO-IAGOWNOFSA-N

2.1.4 Canonical SMILES

CCCCCC1=CC(=C2C3C=C(CCC3C(OC2=C1)(C)C)C)O

2.1.5 Isomeric SMILES

CCCCCC1=CC(=C2[C@@H]3C=C(CC[C@H]3C(OC2=C1)(C)C)C)O

2.2 Other Identifiers

2.2.1 UNII

7J8897W37S

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 9 Ene Tetrahydrocannabinol

2. 9-ene-tetrahydrocannabinol

3. Delta(1)-tetrahydrocannabinol

4. Delta(1)-thc

5. Delta(9)-tetrahydrocannabinol

6. Delta(9)-thc

7. Marinol

8. Tetrahydrocannabinol

9. Tetrahydrocannabinol, (6a-trans)-isomer

10. Tetrahydrocannabinol, (6ar-cis)-isomer

11. Tetrahydrocannabinol, (6as-cis)-isomer

12. Tetrahydrocannabinol, Trans Isomer

13. Tetrahydrocannabinol, Trans-(+-)-isomer

14. Tetrahydrocannabinol, Trans-isomer

15. Thc

2.3.2 Depositor-Supplied Synonyms

1. Tetrahydrocannabinol

2. Marinol

3. Delta9-tetrahydrocannabinol

4. Delta9-thc

5. Delta-9-tetrahydrocannabinol

6. 1972-08-3

7. Abbott 40566

8. Deltanyne

9. Delta-9-thc

10. Delta(9)-thc

11. Thc

12. Dronabinolum

13. Delta(1)-tetrahydrocannabinol

14. Delta(9)-tetrahydrocannabinol

15. Delta1-thc

16. 1-trans-delta-9-tetrahydrocannabinol

17. Delta(sup 1)-thc

18. Delta(sup 9)-thc

19. Qcd 84924

20. Sp 104

21. Namisol

22. (-)-delta9-trans-tetrahydrocannabinol

23. 9-tetrahydrocannabinol

24. 1-trans-delta9-tetrahydrocannabinol

25. Qcd-84924

26. Delta1-tetrahydrocannabinol

27. Delta(9)-tetrahydrocannibinol

28. .delta.9-tetrahydrocannabinol

29. Syndros

30. Delta(sup 1)-tetrahydrocannabinol

31. Delta(sup 9)-tetrahydrocannabinol

32. .delta.1-thc

33. .delta.9-thc

34. L-delta1-trans-tetrahydrocannabinol

35. Cannabinol, Delta1-tetrahydro-

36. Ccris 4726

37. (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol

38. Chebi:66964

39. 3-pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6h-dibenzo(b,d)pyran-1-ol

40. Chembl465

41. Tetrahydrocannabinols (-)-delta1-3,4-trans-form

42. Nsc-134454

43. (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol

44. .delta.-9-tetrahydrocannabinol

45. Abbott-40566

46. 6465-30-1

47. Cannabinol, 1-trans-delta(sup 9)-tetrahydro-

48. J882f

49. 6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol

50. Sp-104

51. 6h-dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar-trans)-

52. 7j8897w37s

53. Dronabinolum [latin]

54. Tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol

55. 6,6,9-trimethyl-3-pentyl-7,8,9,10-tetrahydro-6h-dibenzo(b,d)pyran-1-ol

56. Tetrahydrocannabinols (-)-trans-.delta.9-form

57. (6ar,10ar)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol

58. 6h-dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar,10ar)-

59. (-)-.delta.9-thc

60. Compassia

61. Relivar

62. (l)-.delta.1-tetrahydrocannabinol

63. (-)-.delta.1-tetrahydrocannabinol

64. (-)-.delta.9-tetrahydrocannabinol

65. L-.delta.1-trans-tetrahydrocannabinol

66. L-trans-.delta.9-tetrahydrocannabinol

67. (6ar-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol

68. 6h-dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar,10ar)-

69. (-)-.delta.9-trans-tetrahydrocannabinol

70. (-)-trans-.delta.9-tetrahydrocannabinol

71. Marinol (tn)

72. Dea No. 7369

73. Delta1-tetrahydrocannabinol (van)

74. Delta9-tetrahydrocannabinol (van)

75. Dronabinol (usp/inn)

76. .delta.1-tetrahydrocannabinol

77. Tetrahydrocannabinol Delta9

78. (-)-trans-delta9-thc

79. (l)-delta(sup 1)-tetrahydrocannabinol

80. Cannabinol, .delta.1-tetrahydro-

81. 1-trans-delta(sup 9)-tetrahydrocannabinol

82. .delta.9-trans-tetrahydrocannabinol

83. (l)-delta1-tetrahydrocannabinol

84. L-.delta.1-tetrahydrocannabinol

85. (-)-delta1-tetrahydrocannabinol

86. (-)-delta9-tetrahydrocannabinol

87. Delta9-trans-tetrahydrocannabinol

88. Hsdb 6471

89. Trans-delta9-tetrahydrocannabinol

90. (6ar,10ar)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo[b,d]pyran-1-ol

91. (6ar-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo[b,d]pyran-1-ol

92. Cat-310

93. 6h-dibenzo(b,d)pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, Trans-

94. L-trans-delta9-tetrahydrocannabinol

95. (-)-delta(sup 1)-3,4-trans-tetrahydrocannabinol

96. 6h-dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar-trans)-

97. Drg-0138

98. Tci

99. 14c-.delta.1-tetrahydrocannabinol

100. Trans-.delta.9-tetrahydrocannabinol

101. (-)-trans-delta1-tetrahydrocannabinol

102. (-)-trans-delta9-tetrahydrocannabinol

103. Nsc 134454

104. .delta.-9-thc

105. 1-trans-delta(sup9)-tetrahydrocannabinol

106. Dronabinol (synthetic)

107. .delta.(sup9)-thc

108. 3ls4

109. Dronabinol [inn]

110. (-)-3,4-trans-delta1-tetrahydrocannabinol

111. 1-trans-.delta.(sup9)-tetrahydrocannabinol

112. Dronabinol [hsdb]

113. Dronabinol [usan]

114. Dsstox_cid_1327

115. (-)-.delta.(sup9)-trans-tetrahydrocannabinol

116. Dronabinol [vandf]

117. Epitope Id:224552

118. Dronabinol [mart.]

119. Schembl4609

120. Delta 9-tetrahydrocannabinol

121. Delta-9 Tetrahydrocannabinol

122. Dronabinol [who-dd]

123. Dsstox_rid_76083

124. Trans-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6h-dibenzo(b,d)pyran-1-ol

125. Dsstox_gsid_21327

126. Bidd:gt0427

127. Dronabinol [usan:usp:inn]

128. Gtpl2424

129. Cannabinol, Tetrahydro- (6ci)

130. Dronabinol [orange Book]

131. Dtxsid6021327

132. Unii-7j8897w37s

133. Bdbm60994

134. Dronabinol [usp Monograph]

135. Dtxsid001038830

136. Us9416103, Delta9-thc

137. (+/-)-delta9-tetrahydrocannabinol

138. Int-0010

139. Zinc1530625

140. Tox21_112616

141. Bdbm50007391

142. Nsc134454

143. Pdsp2_000714

144. Cannabinol, Delta1-tetrahydro- (7ci)

145. Db00470

146. Int-0010/06

147. (-)-delta9-tetrahydrocannabinol Solution

148. Cas-1972-08-3

149. Tetrahydrocannabinol, Delta-9 Trans

150. Synthetic Thc In Sesame Oil / Soft Gelatin

151. C06972

152. Cannabinol, 1-trans-.delta.(sup9)-tetrahydro-

153. D00306

154. Dronabinol In Sesame Oil In Soft Gelatin Capsule

155. Q190067

156. (-)-.delta.1-3,4-trans-tetrahydrocannabinol

157. (-)-delta9-thc (dronabinol) 0.1 Mg/ml In Methanol

158. (-)-delta9-thc (dronabinol) 1.0 Mg/ml In Methanol

159. (-)-delta9-thc (dronabinol) 5.0 Mg/ml In Methanol

160. Delta9-tetrahydrocannabinol Solution, Ethanol Solution

161. Delta9-tetrahydrocannabinol 250 Microg/ml In Acetonitrile

162. Tetrahydrocannabinols (-)-trans-.delta.9-form [mi]

163. Delta-9-tetrahydrocannabinol (cannabis Sativa Extract)

164. 6h-dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-

165. (-)-delta9-tetrahydrocannabinol (delta9-thc) 100 Microg/ml In Methanol

166. (-)-delta9-tetrahydrocannabinol (delta9-thc) 1000 Microg/ml In Methanol

167. 6,9-trimethyl-3-pentyl-7,8,9,10-tetrahydro-6h-dibenzo[b,d]pyran-1-ol

168. 6h-dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, Trans-

169. (-)-(6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol

170. (-)-delta(sup 1)-3,4-trans-tetrahydrocannabinol(l)-delta(sup 1)-tetrahydrocannabinol

171. (10r,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol

172. (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6h,6ah,7h,8h,10ah-benzo[c]isochromen-1-ol

173. (s)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol

174. 6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol(deltae-9-thc)

175. 6h-dibenzo[b, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6ar-trans)-

176. Delta-9-tetrahydrocannabinol, United States Pharmacopeia (usp) Reference Standard

177. (-)-delta9-tetrahydrocannabinol Solution, ~1 Mg/ml In Ethanol, Analytical Standard, For Drug Analysis

178. (-)-trans-delta9-thc Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material

179. (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-dibenzo(b,d)pyran-1-ol

180. 6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6h-benzo[c]chromen-1-ol(delta9-thc(delta9-tetrahydrocannabinol))

181. 8,8-dimethyl-11-methylene-5-pentyl-3,4,8a,9,10,11,12,12a-octahydro-2h,8h-1,7-dioxa-benzo[c]phenanthrene

182. Delta9-tetrahydrocannabinol Solution, 1.0 Mg/ml In Methanol, Analytical Standard, For Drug Analysis

2.4 Create Date

2005-03-26

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₃₀O₂
Molecular Weight	314.5 g/mol
XLogP3	7
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	4
Exact Mass	314.224580195 g/mol
Monoisotopic Mass	314.224580195 g/mol
Topological Polar Surface Area	29.5 Å²
Heavy Atom Count	23
Formal Charge	0
Complexity	439
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 4
Drug Name	Dronabinol
PubMed Health	Dronabinol (By mouth)
Drug Classes	Antiemetic
Drug Label	Dronabinol is a cannabinoid designated chemically as (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol. Dronabinol has the following empirical and structural formulas: Dronabinol, the active ingredient in MARINOL...
Active Ingredient	Dronabinol
Dosage Form	Capsule
Route	Oral
Strength	2.5mg; 5mg; 10mg
Market Status	Prescription
Company	Svc Pharma; Insys Therap; Akorn

2 of 4
Drug Name	Marinol
PubMed Health	Dronabinol (By mouth)
Drug Classes	Antiemetic
Drug Label	Dronabinol is a cannabinoid designated chemically as (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol. Dronabinol has the following empirical and structural formulas: Dronabinol, the active ingredient in MARINOL...
Active Ingredient	Dronabinol
Dosage Form	Capsule
Route	Oral
Strength	2.5mg; 5mg; 10mg
Market Status	Prescription
Company	Abbvie

3 of 4
Drug Name	Dronabinol
PubMed Health	Dronabinol (By mouth)
Drug Classes	Antiemetic
Drug Label	Dronabinol is a cannabinoid designated chemically as (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol. Dronabinol has the following empirical and structural formulas: Dronabinol, the active ingredient in MARINOL...
Active Ingredient	Dronabinol
Dosage Form	Capsule
Route	Oral
Strength	2.5mg; 5mg; 10mg
Market Status	Prescription
Company	Svc Pharma; Insys Therap; Akorn

4 of 4
Drug Name	Marinol
PubMed Health	Dronabinol (By mouth)
Drug Classes	Antiemetic
Drug Label	Dronabinol is a cannabinoid designated chemically as (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol. Dronabinol has the following empirical and structural formulas: Dronabinol, the active ingredient in MARINOL...
Active Ingredient	Dronabinol
Dosage Form	Capsule
Route	Oral
Strength	2.5mg; 5mg; 10mg
Market Status	Prescription
Company	Abbvie

4.2 Therapeutic Uses

Hallucinogens Psychotropic Drugs Analgesics, Non-Narcotic Cannabinoid Receptor Agonists

National Library of Medicine's Medical Subject Headings online file (MeSH, 2017); Available from, as of September 13, 2017: https://meshb.nlm.nih.gov/record/ui?ui=D013759

Dronabinol capsules are indicated for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for DRONABINOL capsule (September 2015). Available from, as of September 13, 2017: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=68b4168b-5782-4e68-a25a-5b4e4408dbce

Dronabinol is used for the treatment of anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS). Dronabinol is designated an orphan drug by the US Food and Drug Administration (FDA) for use in this condition.

American Society of Health-System Pharmacists 2011; Drug Information 2011. Bethesda, MD. 2011

/EXPL THER/ BACKGROUND: Cannabis use disorder is associated with substantial morbidity and, after alcohol, is the most common drug bringing adolescents and adults into treatment. At present, there are no FDA-approved medications for cannabis use disorder. Combined pharmacologic interventions might be particularly useful in mitigating withdrawal symptoms and promoting abstinence. OBJECTIVE: The purpose of this study was to evaluate the safety and efficacy of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol, a naturally occurring pharmacologically active component of marijuana, and lofexidine, an alpha-2 agonist, in treating cannabis dependence. METHODS: One hundred fifty six cannabis-dependent adults were enrolled and following a 1-week placebo lead-in phase 122 were randomized in a double-blind, placebo-controlled, 11-week trial. Participants were randomized to receive dronabinol 20 mg three times a day and lofexidine 0.6 mg three times a day or placebo. Medications were maintained until the end of week eight, were then tapered over two weeks and patients were monitored off medications during the last study week. All participants received weekly motivational enhancement and relapse prevention therapy. Marijuana use was assessed using the timeline follow-back method. RESULTS: There was no significant difference between treatment groups in the proportion of participants who achieved 3 weeks of abstinence during the maintenance phase of the trial (27.9% for the medication group and 29.5% for the placebo group), although both groups showed a reduction over time. CONCLUSIONS: Based on this treatment study, the combined intervention did not show promise as a treatment for cannabis use disorder.

PMID:26711160 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729291 Levin FR et al; Drug Alcohol Depend 159: 53-60 (2016)

For more Therapeutic Uses (Complete) data for delta 9-Tetrahydrocannabinol (10 total), please visit the HSDB record page.

4.3 Drug Warning

Dronabinol capsules are contraindicated in any patient who has a known sensitivity to dronabinol or any of its ingredients. It contains cannabinoid and sesame oil and should never be used by patients allergic to these substances.

Patients receiving treatment with dronabinol capsules should be specifically warned not to drive, operate machinery, or engage in any hazardous activity until it is established that they are able to tolerate the drug and to perform such tasks safely.

Seizure and seizure-like activity have been reported in patients receiving dronabinol capsules during marketed use of the drug and in clinical trials. Dronabinol capsules should be used with caution in patients with a history of seizure disorder because dronabinol capsules may lower the seizure threshold. A causal relationship between dronabinol capsules and these events has not been established. Dronabinol capsules should be discontinued immediately in patients who develop seizures and medical attention should be sought immediately.

Dronabinol capsules should be used with caution in patients with cardiac disorders because of occasional hypotension, possible hypertension, syncope, or tachycardia.

For more Drug Warnings (Complete) data for delta 9-Tetrahydrocannabinol (15 total), please visit the HSDB record page.

4.4 Minimum/Potential Fatal Human Dose

The estimated lethal human dose of intravenous dronabinol is 30 mg/kg (2100 mg/70 kg).

4.5 Drug Indication

For the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments

FDA Label

Treatment of central and peripheral neuropathic pain

Treatment of spasticity

5 Pharmacology and Biochemistry

5.1 Pharmacology

Marinol may has complex effects on the central nervous system (CNS), including cannabinoid receptors. Dronabinol may inhibit endorphins in the emetic center, suppress prostaglandin synthesis, and/or inhibit medullary activity through an unspecified cortical action.

5.2 MeSH Pharmacological Classification

Cannabinoid Receptor Agonists

Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS. (See all compounds classified as Cannabinoid Receptor Agonists.)

Hallucinogens

Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise. (See all compounds classified as Hallucinogens.)

Analgesics, Non-Narcotic

A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS. (See all compounds classified as Analgesics, Non-Narcotic.)

Psychotropic Drugs

A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

DRONABINOL

5.3.2 FDA UNII

7J8897W37S

5.3.3 Pharmacological Classes

Cannabinoids [CS]; Cannabinoid [EPC]

5.4 ATC Code

A - Alimentary tract and metabolism

A04 - Antiemetics and antinauseants

A04A - Antiemetics and antinauseants

A04AD - Other antiemetics

A04AD10 - Dronabinol

5.5 Absorption, Distribution and Excretion

Absorption

Dronabinol capsules are almost completely absorbed (90 to 95%) after single oral doses. Due to the combined effects of first pass hepatic metabolism and high lipid solubility, only 10 to 20% of the administered dose reaches the systemic circulation. After oral administration, dronabinol has an onset of action of approximately 0.5 to 1 hours and peak effect at 2 to 4 hours. Following BID dosing of 2.5mg of dronabinol, Cmax was found to be 1.32ng/mL with a median Tmax of 1.00 hr.

Route of Elimination

Dronabinol and its biotransformation products are excreted in both feces and urine. Because of its large volume of distribution, dronabinol and its metabolites may be excreted at low levels for prolonged periods of time. Following single dose administration, low levels of dronabinol metabolites have been detected for more than 5 weeks in the urine and feces.

Volume of Distribution

Dronabinol has a large apparent volume of distribution, approximately 10 L/kg, because of its lipid solubility.

Clearance

Values for clearance average about 0.2 L/kg-hr, but are highly variable due to the complexity of cannabinoid distribution.

To establish a fast sensitive, reproducible LC-MS/MS method to study pharmacokinetic properties of THC, and compare relative bioavailability of THC and its solid dispersion in mice. 200 mice were divided randomly into two groups, and administered orally with THC and THC-solid dispersion after fasting (calculate on THC:400 mg x kg(-1)), used HPLC-MS/MS method to determine the THC concentration of each period at the following times: baseline ( predose ), 15, 30, 45 min, 1, 1.5, 2, 3, 4, 6, 24 hr after dosing. Calculating the pharmacokinetic parameters according to the C-t curv, and then use the Phoenix WinNonlin software for data analysis. The calibration curves were linear over the range 9.06-972 ug/L for THC (R2 = 0.999). The limit of detection (LOD) was 0.7 ug/L, respectively. The average extraction recoveries for THC was above 75%, The methodology recoveries were between 79% and 108%. The intra-day and inter-day RSD were less than 13%, the stability test showed that the plasma samples was stable under different conditions (RSD < 15%). The precision, accuracy, recovery and applicability were found to be adequate for pharmacokinetic studies. Pharmacokinetic parameters of THC and THC-solid dispersion orally to mice shows as fllows: T(max), were 60 and 15 min, AUC(0-t) were 44 00.43 and 57 497.81 mg x L(-1) x min, AUC(0-infinity) were 51226.00 and 68031.48 mg/L x min, MRT(0-infinity) were 596.915 6, 661.747 7 min, CL(z)/F were 0.007 809 and 0.005 88 L/min x kg. Compared with THC, the MRT and t1/2 of the THC-solid dispersion were all slightly extended, the t(max) was significantly reduced, AUC(0-24 hr), AUC(0-infinity) and C(max) were all significantly higher, the relative bioavailability of THC-solid dispersion is 1.34 times of THC. The results of the experiment shows that the precision, accuracy, recovery and applicability were found to be adequate for the pharmacokinetic studies. After oral administration to mice, the relative bioavailability of THC-solid dispersion show significant improvement compared to THC.

PMID:24956859 Liao L et al; Zhongguo Zhong Yao Za Zhi 39 (6): 1101-6 (2014)

/MILK/ Marijuana has not been well studied, but tetrahydrocannabinol can reach rather high levels in /breast/ milk, particularly with heavy use. Although adverse effects in infants have not been reported, breast feeding should probably be avoided in heavy users and during therapeutic dronabinol use. Breast feeding should probably be withheld for several hr after occasional marijuana use. Caution should also be used to avoid exposing the infant to marijuana smoke.

Knoben, J.E. and P.O. Anderson (eds.) Handbook of Clinical Drug Data. 6th ed. Bethesda, MD: Drug Intelligence Publications, Inc. 1988., p. 178

There is a great concern about the safety of THC-based drugs in older people (=65 years), as most of THC-trials did not include such group. In this phase 1, randomized, double-blind, double-dummy, placebo-controlled, cross-over trial, we evaluated the safety and pharmacokinetics of three oral doses of Namisol(), a novel THC in tablet form, in older subjects. Twelve healthy older subjects (6 male; mean age 72+/-5 years) randomly received a single oral dose of 3 mg, 5 mg, or 6.5 mg of THC or matching placebo, in a crossover manner, on each intervention day. The data for 11 subjects were included in the analysis. The data of 1 subject were excluded due to non-compliance to study medication. THC was safe and well tolerated. The most frequently reported adverse events (AEs) were drowsiness (27%) and dry mouth (11%). Subjects reported more AEs with THC 6.5mg than with 3mg (p=0.048), 5mg (p=0.034) and placebo (p=0.013). There was a wide inter-individual variability in plasma concentrations of THC. Subjects for whom the Cmax fell within the sampling period (over 2hr), Cmax was 1.42-4.57 ng/mL and Tmax was 67-92 min. The AUC0-2 hr (n=11) was 1.67-3.51 ng/mL. Overall, the pharmacodynamic effects of THC were smaller than effects previously reported in young adults. In conclusion, THC appeared to be safe and well tolerated by healthy older individuals. Data on safety and effectiveness of THC in frail older persons are urgently required, as this population could benefit from the therapeutic applications of THC.

PMID:25035121 Ahmed AI et al; Eur Neuropsychopharmacol 24 (9): 1475-82 (2014)

RATIONALE: Data on safety, pharmacodynamics, and pharmacokinetics of tetrahydrocannabinol (THC) are lacking in dementia patients. METHODS: In this randomized, double-blind, placebo-controlled, crossover trial, we evaluated the safety, pharmacodynamics, and pharmacokinetics of THC in ten patients with dementia (mean age 77.3 +/-5.6). For 12 weeks, participants randomly received oral THC (weeks 1-6, 0.75 mg; weeks 7-12, 1.5 mg) or placebo twice daily for 3 days, separated by a 4-day washout period. RESULTS: Only 6 of the 98 reported adverse events were related to THC. Visual analog scale (VAS) feeling high, VAS external perception, body sway-eyes-open, and diastolic blood pressure were not significantly different with THC. After the 0.75-mg dose, VAS internal perception (0.025 units; 95% CI 0.010-0.040) and heart rate (2 beats/min; 95% CI 0.4-3.8) increased significantly. Body sway-eyes-closed increased only after 1.5 mg (0.59 deg/s; 95% CI 0.13-1.06). Systolic blood pressure changed significantly after both doses of THC (0.75 mg, -7 mmHg, 95% CI -11.4, -3.0; 1.5 mg, 5 mmHg, 95% CI 1.0-9.2). The median T max was 1-2 hr, with THC pharmacokinetics increasing linearly with increasing dose, with wide interindividual variability (CV% up to 140%). The mean C max (ng/mL) after the first dose (0-6 hr) was 0.41 (0.18-0.90) for the 0.75-mg dose and 1.01 (0.53-1.92) for the 1.5-mg dose. After the second dose (6-24 hr), the C max was 0.50 (0.27-0.92) and 0.98 (0.46-2.06), respectively. CONCLUSIONS: THC was rapidly absorbed and had dose-linear pharmacokinetics with considerable interindividual variation. Pharmacodynamic effects, including adverse events, were minor. Further studies are warranted to evaluate the pharmacodynamics and efficacy of higher THC doses in older persons with dementia.

PMID:25752889 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480847 Ahmed AI et al; Psychopharmacology (Berl) 232 (14): 2587-95 (2015)

For more Absorption, Distribution and Excretion (Complete) data for delta 9-Tetrahydrocannabinol (32 total), please visit the HSDB record page.

5.6 Metabolism/Metabolites

THC is primarily metabolized in the liver by microsomal hydroxylation and oxidation reactions catalyzed by Cytochrome P450 enzymes. 11-hydroxy-9-tetrahydrocannabinol (11-OH-THC) is the primary active metabolite, capable of producing psychological and behavioural effects, which is then metabolized into 11-nor-9-carboxy- 9-tetrahydrocannabinol (THC-COOH), THC's primary inactive metabolite. Dronabinol and its principal active metabolite, 11-OH-delta-9-THC, are present in approximately equal concentrations in plasma. Concentrations of both parent drug and metabolite peak at approximately 0.5 to 4 hours after oral dosing and decline over several days.

The analgesic activity of delta-8- and delta-9-THC is mainly due to the 11-hydroxy metabolite.

Wilson RS, May EL; J Med Chem 18: 700-3 (1975) as cited in DHHS/NIDA; Research Monograph Series 52: Testing Drugs for Physical Dependence Potential and Abuse Liability p.71 (1984) DHHS Pub No. (ADM)87-1332

The metabolism of delta(9)-tetrahydrocannabinol (THC) is relatively complex, and over 80 metabolites have been identified. However, much less is known about the formation and fate of cannabinoid conjugates. Bile excretion is known to be an important route for the elimination of phase II metabolites. A liquid chromatography-tandem mass spectrometry LC-MS/MS procedure for measuring cannabinoids in oral fluid was adapted, validated and applied to 10 bile samples. THC, 11-hydroxy-delta(9)-tetrahydrocannabinol (11-OH-THC), 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol (THCCOOH), cannabinol (CBN), cannabidiol (CBD), delta(9)-tetrahydrocannabinolic acid A (THC-A), 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol glucuronide (THCCOOH-gluc) and delta(9)-tetrahydrocannabinol glucuronide (THC-gluc) were determined following solid-phase extraction and LC-MS/MS. High concentrations of THCCOOH-gluc were found in bile samples (range: 139-21,275 ng/mL). Relatively high levels of THCCOOH (7.7-1548 ng/mL) and THC-gluc (38-1366 ng/mL) were also measured. THC-A, the plant precursor of THC, was the only cannabinoid that was not detected. These results show that biliary excretion is an important route of elimination for cannabinoids conjugates and that their enterohepatic recirculation is a significant factor to consider when analyzing blood elimination profiles of cannabinoids. Furthermore, we suggest that the bile is the matrix of choice for the screening of phase II cannabinoid metabolites.

PMID:22980143 Fabritius M et al; Forensic Sci Int 223 (1-3): 114-8 (2012)

The presence of the metabolite 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (C-THC) in hair is generally accepted as the definitive proof of delta-9-tetrahydrocannabinol (THC) ingestion. During hair analysis, the removal of any potential C-THC external contamination that could result from marijuana smoke or close personal contact via a wash procedure is critical. Here, we performed a series of experiments to demonstrate that C-THC is the reliable indicator of marijuana ingestion when paired with the correct washing procedure to remove potential external contamination.

PMID:27185816 Hill VA et al; J Anal Toxicol 40 (5): 345-9 (2016)

Dronabinol undergoes extensive first-pass hepatic metabolism, primarily by microsomal hydroxylation, yielding both active and inactive metabolites. Dronabinol and its principal active metabolite, 11-OH-delta-9-THC, are present in approximately equal concentrations in plasma.

For more Metabolism/Metabolites (Complete) data for delta 9-Tetrahydrocannabinol (15 total), please visit the HSDB record page.

Delta-9-Tetrahydrocannabinol has known human metabolites that include 11-hydroxy-delata-Tetrahydrocannabinol, 7-hydroxy-delta-9-Tetrahydrocannabinol, 7alpha-hydroxy-delta-9-Tetrahydrocannabinol, 8-hydroxy-delta-9-Tetrahydrocannabinol, and 8alpha-hydroxy-delta-9-Tetrahydrocannabinol.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560

5.7 Biological Half-Life

The elimination phase of dronabinol can be described using a two compartment model with an initial (alpha) half-life of about 4 hours and a terminal (beta) half-life of 25 to 36 hours.

After the pseudo-equilibrium is reached, THC is then slowly eliminated. This slow elimination is primarily due to the slow return of THC from sequestered tissues to blood. The terminal half-life of THC is approximately 1 day. /Several investigators have/ suggested terminal half-life /ranging between/ 19 to 36 hours. There are no significant differences in plasma profiles for chronic and infrequent users or in half-lives in moderate users before and after a 2-week exposure of THC.

DHHS/NIDA; Research Monograph Series 79: Structure-Activity Relationships of the Cannabinoids p.XX (1987) DHHS Pub No. (ADM)90-1534

The elimination half-life of dronabinol (delta-1-tetrahydrocannabinol) in 3 chronic marihuana users following smoking 4 cigarettes over a 2 day period is reported. The elimination half-life in blood plasma was calculated to be 4.1 days (range 2.9-5.0 days).

Johansson E et al; J Pharm Pharmcol 40: 374-5 (1988)

The terminal plasma half-life of metabolites from THC administration is approximately 50 hours, which is longer than that of THC. ... /Metabolites/

DHHS/NIDA; Research Monograph Series 79: Structure-Activity Relationships of the Cannabinoids p.180 (1987) DHHS Pub No. (ADM)90-1534

5.8 Mechanism of Action

Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes.

The availability of potent synthetic agonists for cannabinoid receptors has facilitated our understanding of cannabinoid actions on synaptic transmission in the central nervous system. Moreover, the ability of these compounds to inhibit neurotransmitter release at many central synapses is thought to underlie most of the behavioral effects of cannabinoid agonists. However, despite the widespread use and misuse of marijuana, and recognition of its potential adverse psychological effects in humans, comparatively few studies have examined the actions of its primary psychoactive constituent, delta(9)-tetrahydrocannabinol (THC), at well-defined synaptic pathways. Here we examine the recent literature describing the effects of acute and repeated THC exposure on synaptic function in several brain regions and explore the importance of these neurobiological actions of THC in drug addiction.

PMID:23209160 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721267 Hoffman AF, Lupica CR; Cold Spring Harb Perspect Med 3 (8). pii: a012237 (2013)

Cannabis has potential therapeutic use but tetrahydrocannabinol (THC), its main psychoactive component, appears as a risk factor for ischemic stroke in young adults. We therefore evaluate the effects of THC on brain mitochondrial function and oxidative stress, key factors involved in stroke. Maximal oxidative capacities V max (complexes I, III, and IV activities), V succ (complexes II, III, and IV activities), V tmpd (complex IV activity), together with mitochondrial coupling (V max/V 0), were determined in control conditions and after exposure to THC in isolated mitochondria extracted from rat brain, using differential centrifugations. Oxidative stress was also assessed through hydrogen peroxide (H2O2) production, measured with Amplex Red. THC significantly decreased V max (-71%; P<0.0001), V succ (-65%; P<0.0001), and V tmpd (-3.5%; P<0.001). Mitochondrial coupling (V max/V 0) was also significantly decreased after THC exposure (1.8+/-0.2 versus 6.3+/-0.7; P<0.001). Furthermore, THC significantly enhanced H2O2 production by cerebral mitochondria (+171%; P<0.05) and mitochondrial free radical leak was increased from 0.01+/-0.01 to 0.10+/-0.01% (P<0.001). Thus, THC increases oxidative stress and induces cerebral mitochondrial dysfunction. This mechanism may be involved in young cannabis users who develop ischemic stroke since THC might increase patient's vulnerability to stroke.

PMID:25654095 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310259 Wolff V et al; Biomed Res Int 2015: 323706 (2015)

MDSCs are potent immunosuppressive cells that are induced during inflammatory responses, as well as by cancers, to evade the antitumor immunity. We recently demonstrated that marijuana cannabinoids are potent inducers of MDSCs. In the current study, we investigated the epigenetic mechanisms through which THC, an exogenous cannabinoid, induces MDSCs and compared such MDSCs with the naive MDSCs found in BM of BL6 (WT) mice. Administration of THC into WT mice caused increased methylation at the promoter region of DNMT3a and DNMT3b in THC-induced MDSCs, which correlated with reduced expression of DNMT3a and DNMT3b. Furthermore, promoter region methylation was decreased at Arg1 and STAT3 in THC-induced MDSCs, and consequently, such MDSCs expressed higher levels of Arg1 and STAT3. In addition, THC-induced MDSCs secreted elevated levels of S100A8, a calcium-binding protein associated with accumulation of MDSCs in cancer models. Neutralization of S100A8 by use of anti-S100A8 (8H150) in vivo reduced the ability of THC to trigger MDSCs. Interestingly, the elevated S100A8 expression also promoted the suppressive function of MDSCs. Together, the current study demonstrates that THC mediates epigenetic changes to promote MDSC differentiation and function and that S100A8 plays a critical role in this process.

PMID:25713087 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370051 Sido JM et al; J Leukoc Biol 97 (4): 677-88 (2015)

Dronabinol is an orally active cannabinoid which, like other cannabinoids, has complex effects on the central nervous system (CNS), including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol and other cannabinoids.

For more Mechanism of Action (Complete) data for delta 9-Tetrahydrocannabinol (10 total), please visit the HSDB record page.

API SUPPLIERS